89bio's pegozafermin could be major player in the dyslipidemia market

California, USA-based clinical-stage biopharmaceutical company 89bio’s (Nasdaq: ETNB) pegazofermin has potential to become one of the major players in the dyslipidemia space if it is successful in Phase III clinical trials, says data and analytics firm GlobalData.

The Food and Drug Administration (FDA) recently supported the advancement of pegozafermin into two Phase III clinical trials, the first due to launch in the first half of 2023. If successful, pegozafermin has potential to address an unmet need of efficacious therapies with improved side-effect profiles for hypertriglyceridemia. According to the analyst consensus forecast on the GlobalData Pharma Intelligence Center, the drug is expected to reach $438 million by 2028. Pegozafermin is currently the only drug being investigated by 89bio and is also in Phase II trials for non-alcoholic steatohepatitis (NASH).

Earlier this month, 89bio said that, based on the results from its previous trials and recent data from other NASH product candidates, it remains confident that the trial outcome could support the transition into Phase III.